VistaGen Therapeutics Reports Fiscal Year 2019 Results and Provides CNS Pipeline Overview Jun 25, 2019
VistaGen Announces Positive Preclinical Data Supporting AV-101's Potential For Treating Levodopa-Induced Dyskinesia In Patients With Parkinson's Disease, Without The Psychological Side Effects And Safety Concerns Of Amantadine Jun 20, 2019
VistaGen Announces Positive Preclinical Data Supporting AV-101's Potential for Treating Neuropathic Pain Comparable to Pregabalin (Lyrica(R)), without its Side Effects May 30, 2019
VistaGen Reports Top Line Results from NIMH's Exploratory Study of AV-101 Monotherapy for Treatment-Resistant Depression May 2, 2019
VistaGen Therapeutics to Participate in the William Blair 3rd Annual Late-Stage Therapeutics Conference on April 4, 2019 Apr 3, 2019
Positive Pilot Phase 3 Data Position VistaGen's PH94B Neuroactive Nasal Spray for Pivotal Phase 3 Development as a Novel, As-Needed Treatment for Social Anxiety Disorder Apr 1, 2019
VistaGen Therapeutics Receives Australian Patent for Treatment of Depression with AV-101 Mar 28, 2019
VistaGen Therapeutics to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19, 2019 Mar 14, 2019
VistaGen Therapeutics Receives Notice of Allowance for Additional U.S. Patent Regarding Methods of Production for AV-101 Mar 13, 2019
